esophageal cancer
Conditions
Interventions
Experimental: Chemoradiation with Late Course Small Field Boost by IMRT:Radiation: Radiation therapy. Radiotherapy at a dose of 2 Gy will be given to PTV1 to 50 Gy first, and then another 16 Gy will
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histological or cytologic diagnosis of esophageal squamous carcinoma; 2. KPS = 70; 3. Aged 18-75 years; 4. Joined the study voluntarily and signed informed consent form; 5. Not have received any prior anticancer therapy; Local advanced esophageal cancer (T2-4N0-1M0-1a,TxN1M0-1a,TxNxM1a, AJCC 6th); 6. No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin =9 g/dL, WBC=3x109/L, Neutrophils (ANC )=1.5x10^9/L, platelet count =100x 10^9/L, TBIL<1.5 x ULN, ALT and AST ? 2.5 x ULN, creatinine ? 1.5 x ULN; 7. Use of an effective contraceptive for adults to prevent pregnancy; 8. Life expectancy of more than 3 months.
Exclusion criteria
Exclusion criteria: 1. After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting therapy; 2. Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years; 3. Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives; 4. Drug addiction; 5. AIDS; 6. Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior; 7. Patient who has metastasis such as lung, liver metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local control rate;Number of participants with adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free-Survival;Overall survival;Response Rate; | — |
Countries
China
Contacts
Public ContactKailiang Wu
Fudan University Shanghai Cancer Center
Outcome results
None listed